Merck brought in $39.8 billion in 2016 global sales. The U.S. drug giant’s wide-ranging portfolio was crucial to that haul–but the company’s next-generation cancer immunotherapy treatment, Keytruda, is what really set it apart last year. The therapy bested rival Bristol-Myers Squibb’s competing Opdivo in the critical lung cancer space, according to clinical trial data, making it (and Merck) one of the most formidable players in the latest strike on cancer.
Looking for leads, investment insights, or competitive intelligence?
News about Merck
The FDA approved 46 novel drugs in 2017 versus 22 in 2016.
There still aren't any truly effective drugs for Alzheimer's or dementia.
Novartis and Amgen want to find out with an experimental drug.
AbbVie and Alector hope to apply immunotherapy to dementia and Alzheimer's.
This is your Cyber Saturday edition of Fortune's tech newsletter for October 7, 2017.